MetrioPharms drug candidate MP1032 is currently in clinical phase II.
In December 2015, the phase I clinical trial was successfully completed:
The results exceeded the expectations of MetrioPharm's team significantly. Even with six times exceeding the therapeutic dose no adverse reactions to MP1032 were observed in the probands.
In March 2017, the phase IIa clinical trial in patients with moderate-to-severe chronic plaque psoriasis was successfully completed:
The primary objectives of the study were to evaluate the safety and pharmacokinetics (PK) of twice daily 100 mg MP1032 in patients with moderate-to-severe plaque psoriasis. No serious or severe adverse events were reported in patients treated with MP1032. Exploratory analyses regarding the potential effect of the drug on PASI scores suggest a clinically meaningful response in patients who entered the study with a PASI score of 10-20 and achieved appropriate MP1032 exposure values. Further studies using higher doses of MP1032 and longer treatment durations will be conducted to fully evaluate the efficacy of MP1032 in patients with moderate-to-severe plaque psoriasis.
You can find more information about this phase II clinical trial and its results under the search term MetrioPharm at www.clinicaltrialsregister.eu.
Phase II: MP1032 in patients with moderate-to-severe chronic plaque psoriasis
A further phase II trial is planned to be conducted in Germany and Poland as a randomized, double-blind, placebo-controlled study with twice-daily oral dosing. The primary objective of this trial is to evaluate the clinical efficacy and safety of two oral doses of MP1032 (150 mg and 300 mg twice daily) when taken for 12 weeks by patients with moderate-to-severe chronic plaque psoriasis.